Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
Holding LEGN?
Track your performance easily
LEGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$36.92 - $70.13
Previous Close$38.4
Volume2.24M
Average Volume (3M)1.21M
Market Cap
$7.04B
Enterprise Value$6.15B
Total Cash (Recent Filing)$1.28B
Total Debt (Recent Filing)$383.94M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Mar 13, 2025EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding181,911,035
10 Day Avg. Volume1,862,625
30 Day Avg. Volume1,214,360
Standard Deviation0.14
R-Squared0.00153
Alpha0.00843
Financial Highlights & Ratios
Price to Book (P/B)5.58
Price to Sales (P/S)87.43
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue115.29
Enterprise Value/Gross Profit43.64
Enterprise Value/Ebitda-32.13
Forecast
1Y Price Target
$84.00Price Target Upside109.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Legend Biotech News
PremiumCompany Announcements
Legend Biotech’s Q3 2024 Sees Strong Sales Growth
PremiumCompany Announcements
Legend Biotech Reports Strong Sales Growth in Q3 2024
PremiumPre-Earnings
Is LEGN a Buy, Before Earnings?PremiumCompany Announcements
Legend Biotech’s CARVYKTI Shows Promising Myeloma ResultsBulls Say, Bears Say
Bulls Say
Commercial ExpansionThe analyst's outperform rating is supported by the continuous expansion of Carvykti through approvals in earlier lines and regions outside the U.S.
Market ShareCarvykti's 90% market share in BCMA CAR-T in the US and Germany reflects its strong profile that is highly attractive to patients and physicians.
Sales GrowthCarvykti's strong profile, outpatient use, and manufacturing improvement led to an impressive 54% quarter-over-quarter sales growth.
Bears Say
EarningsThe company reported an earnings per share of $(0.34), slightly lower than the consensus estimate.
Market RisksBranded Rx drug prices in China are typically significantly lower and the market is predominantly self-pay, tempering the potential for rapid CARVYKTI sales growth.
Risks And ManufacturingLegend's stock has been weak this year due to a slow manufacturing ramp and concerns about data for ACLX/GILD's anito-cel.
---
Ownership Overview
―
Insiders
17.45% Mutual Funds
18.53% Other Institutional Investors
61.56% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LEGN FAQ
What was Legend Biotech Corporation’s price range in the past 12 months?
Legend Biotech Corporation lowest stock price was $36.92 and its highest was $70.13 in the past 12 months.
What is Legend Biotech Corporation’s market cap?
Currently, no data Available
When is Legend Biotech Corporation’s upcoming earnings report date?
Legend Biotech Corporation’s upcoming earnings report date is Mar 13, 2025 which is in 113 days.
How were Legend Biotech Corporation’s earnings last quarter?
Legend Biotech Corporation released its earnings results on Nov 12, 2024. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.33 by -$0.01.
Is Legend Biotech Corporation overvalued?
According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued.
Does Legend Biotech Corporation pay dividends?
Legend Biotech Corporation does not currently pay dividends.
What is Legend Biotech Corporation’s EPS estimate?
Legend Biotech Corporation’s EPS estimate is -$0.23.
How many shares outstanding does Legend Biotech Corporation have?
Legend Biotech Corporation has 184,288,400 shares outstanding.
What happened to Legend Biotech Corporation’s price movement after its last earnings report?
Legend Biotech Corporation reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.33. Following the earnings report the stock price went up 0.35%.
Which hedge fund is a major shareholder of Legend Biotech Corporation?
Among the largest hedge funds holding Legend Biotech Corporation’s share is RA Capital Management. It holds Legend Biotech Corporation’s shares valued at 366M.
---
Legend Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$84.00 (109.27% Upside)
$84.00 (109.27% Upside)
Blogger Sentiment
Bullish
LEGN Sentiment 75%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 7.0%
Last 30 Days ▲ 7.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.52%
12-Months-Change
Fundamentals
Return on Equity
-28.35%
Trailing 12-Months
Asset Growth
-5.63%
Trailing 12-Months
Company Description
Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Its other pipeline products include LB1910, LB1909, LB1903, and others. Geographically, the company generates a majority of its revenue from North America.
---
LEGN Earnings Call
Q3 2024
0:00 / 0:00
---
LEGN Stock 12 Month Forecast
Average Price Target
$84.00
▲(109.27% Upside)
Technical Analysis
Best Analysts Covering LEGN
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
-4.97%
reiterated a buy rating 2 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -4.97% per trade.
---